Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
RESEARCH TOOLSreports
Holding SWTX?
Track your performance easily
SWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$28.21 - $53.92
Previous Close$41.48
Volume645.35K
Average Volume (3M)1.09M
Market Cap
$3.09B
Enterprise Value$2.72B
Total Cash (Recent Filing)$376.62M
Total Debt (Recent Filing)$6.91M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 04, 2025EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding74,386,403
10 Day Avg. Volume1,987,196
30 Day Avg. Volume1,088,227
Standard Deviation0.18
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.23
Price to Sales (P/S)20.82
Price to Cash Flow (P/CF)-27.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.05
Enterprise Value/Gross Profit540.47
Enterprise Value/Ebitda-15.22
Forecast
1Y Price Target
$66.43Price Target Upside60.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Springworks Therapeutics News
PremiumCompany Announcements
SpringWorks Therapeutics Q3 2024 Results Overview
Bulls Say, Bears Say
Bulls Say
Market ValuationSWTX shares are seen as undervalued into the high-$40s per share range on Ogsiveo in desmoid tumors alone.
Product LaunchHigh physician enthusiasm is driving the US launch and long treatment durations.
Regulatory ApprovalsThe EMA has validated the Marketing Authorization Application for nirogacestat to treat adults with desmoid tumors.
Bears Say
Financial ResultsSpringWorks reported a net loss of $0.72 per share, which was wider than the original estimate of $0.60 per share.
Operational ChallengesTransition to blister packs caused delays for many patients getting their prescriptions refilled.
Sales PerformanceOgsiveo's sales were $49M, falling short of the $52M consensus.
---
Ownership Overview
3.01% Insiders
33.98% Mutual Funds
38.77% Other Institutional Investors
7.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SWTX FAQ
What was Springworks Therapeutics’s price range in the past 12 months?
Springworks Therapeutics lowest stock price was $28.21 and its highest was $53.92 in the past 12 months.
What is Springworks Therapeutics’s market cap?
Currently, no data Available
When is Springworks Therapeutics’s upcoming earnings report date?
Springworks Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were Springworks Therapeutics’s earnings last quarter?
Springworks Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.754 by $0.034.
Is Springworks Therapeutics overvalued?
According to Wall Street analysts Springworks Therapeutics’s price is currently Undervalued.
Does Springworks Therapeutics pay dividends?
Springworks Therapeutics does not currently pay dividends.
What is Springworks Therapeutics’s EPS estimate?
Springworks Therapeutics’s EPS estimate is -$0.65.
How many shares outstanding does Springworks Therapeutics have?
Springworks Therapeutics has 74,386,406 shares outstanding.
What happened to Springworks Therapeutics’s price movement after its last earnings report?
Springworks Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.754. Following the earnings report the stock price went down -1.253%.
Which hedge fund is a major shareholder of Springworks Therapeutics?
Among the largest hedge funds holding Springworks Therapeutics’s share is Maverick Capital ltd. It holds Springworks Therapeutics’s shares valued at 89M.
---
Springworks Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.43 (60.15% Upside)
$66.43 (60.15% Upside)
Blogger Sentiment
Bullish
SWTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.60%
12-Months-Change
Fundamentals
Return on Equity
-59.33%
Trailing 12-Months
Asset Growth
30.20%
Trailing 12-Months
Company Description
Springworks Therapeutics
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
---
SWTX Earnings Call
Q3 2024
0:00 / 0:00
---
SWTX Stock 12 Month Forecast
Average Price Target
$66.43
▲(60.15% Upside)
Technical Analysis
Best Analysts Covering SWTX
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+69.84%
reiterated a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +69.84% per trade.
---